Treatment News

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News


November 26, 2014
Semen Counteracts Effectiveness of HIV Microbicides
An element of semen both lowers the effectiveness of many HIV microbicides and enhances the virus’s infectiousness, possibly explaining why real-world trials of microbicides have fared so poorly.
November 25, 2014
CDC Analyzes Impediments to Viral Suppression in People With HIV
The CDC has reframed the HIV treatment cascade figures to highlight the various reasons why only 30 percent of Americans have a fully suppressed virus.
November 24, 2014
Lower CNS Side Effects, Similar Efficacy for Doravirine Vs. Sustiva
Merck’s doravirine (MK-1439) is comparable to Sustiva (efavirenz) in terms of efficacy, but is linked to fewer central nervous system side effects.
November 21, 2014
There Is a Chance to Build Upon One HIV Vaccine’s Moderate Success
New research suggests that retooling of vaccine found moderately successful could yield efficacy high enough to prevent most HIV infections.
November 20, 2014
Harvoni Cures Almost All People With Hep C Coinfected With HIV
Twelve weeks of Gilead Sciences’ newly approved Harvoni cured nearly all people with genotype 1 of hepatitis C who were coinfected with HIV in a recent trial.
Mother-to-Child HIV Transmission Is Best Prevented With 3 Drugs
Taking a triple-antiretroviral regimen is best for preventing mother-to-child transmission during pregnancy, rather than taking one drug during pregnancy, another during labor and two more after giving birth.
November 19, 2014
U.S. HIV 'Treatment Cascade' Stats Are Dismal Among Western Nations
Compared with other high-income Western nations, the United States HIV treatment cascade figures are remarkably bad.
November 18, 2014
Racial Disparities in the Gay Male HIV Epidemic Appear Entrenched
Black men who have sex with men will likely continue to have disproportionately high HIV rates for decades.
November 17, 2014
High Post-Liver Transplant Survival Rates for People With HIV
HIV-positive people who have liver transplants because of liver cancer have high survival rates.
Age-Related Diseases Not Occurring Earlier for People With HIV
While HIV-positive people do experience higher rates of age-related diseases, they don't experience them at younger ages than HIV-negative people.
November 14, 2014
New Potential HIV Treatment Target Is Discovered
Researchers have identified a new protein that participates in HIV’s replication process, opening the door for development of a potential therapy targeting the protein.
November 13, 2014
Vaginal Ring May Protect Against HIV, Herpes, HPV and Pregnancy
A multipurpose vaginal ring has shown promise in protecting against HIV, genital herpes, HPV and pregnancy in a primate study.
November 12, 2014
Excellent Results for 12 and 18 Weeks of Merck’s Dual Hep C Regimen
Twelve or 18 weeks of Merck’s grazoprevir/elbasvir, with or without ribavirin, cured 91 to 100 percent of hard-to-treat people with genotype 1 of hepatitis C.
HIV Meds Early in Pregnancy Linked to Low Risk of Birth Defects
Pregnant women who take antiretrovirals (ARVs) to treat HIV early in their pregnancies appear to have a low risk of birth defects in their infants.
November 11, 2014
Viread Gel Linked to Lowered Risk of Herpes Among Women
Women who regularly used a Viread (tenofovir)–based vaginal gel had a 46 percent reduced risk of acquiring herpes, according to a secondary analysis of the VOICE trial.
November 10, 2014
Hep C Cure Lowers Risk of Death, Liver Cancer and Transplants
Achieving a cure for hepatitis C through interferon-based treatment reduces the risk of death, liver cancer and needing a liver transplant.
High Success For Harvoni Treating Coinfected Genotype 1
Harvoni (ledipasvir/sofosbuvir) is proving highly successful at treating hepatitis C among people coinfected with HIV and genotype 1 of hep C in an ongoing small trial.
Researchers See New Avenue For HIV Cure: Endogenization
Scientists believe they have identified the means by which two men were “spontaneously cured" of HIV, and that this insight may carve a new cure pathway.
November 07, 2014
Latest Data on PrEP, Though Patchy, Indicates Rising Use Among Men
The use of Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP) is on the rise in the United States, in particular among men.
November 06, 2014
FDA Approves Olysio-Sovaldi Hep C Combo
The FDA has granted approval of Olysio (simeprevir) and Sovaldi (sofosbuvir) to be used in combination to treat genotype 1 of hepatitis C.
FDA Reviews First Single-Tablet HIV Regimen Containing TAF
The pill has the same antiretrovirals as Stribild, but with a new version of tenofovir.
November 04, 2014
Gays May See Monogamy as Barrier to HIV, Even Without Testing
Research suggests that young gay men’s understanding of what constitutes “safer sex” factors in condoms, testing and monogamy.
November 03, 2014
More PrEP Needed To Prevent HIV Via Vaginal Than Anal Sex
Greater dosing of Viread (tenofovir) or Truvada (tenofovir/emtricitabine) as PrEP is needed to reach effective levels in vaginal and cervical tissue than in recal tissue.
More Treatment News

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ



Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Should the U.S. gay blood ban end?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.